|
Objective: To evaluate the clinical efficacy of simvastatin treatment of chronic non-ischemic heart failure . Method selected chronic non- ischemic heart failure were randomly divided into simvastatin and placebo groups, 40 patients in the two groups were treated with standard anti-heart failure treatment , simvastatin simvastatin on the basis of standard treatment 10mg, per night 1 orally for 1 year. Placebo group in the standard treatment based on placebo 10mg, 1 night 1 oral treatment . One day before treatment and 3 months after treatment , the 12-month application of cardiac ultrasound detection: left ventricular ejection fraction ( LVEF ) , left ventricular end-diastolic diameter ( LVEDD ) ; detection 6min walking distance , Minnesota quality of life scores ; serum IL -1 , BNP , APN level ; and record adverse events in the study period . Results: simvastatin and placebo groups each index baseline was no significant difference ; 3 months and 12 months observation point in time : 6min walking distance of the simvastatin group than the placebo group ( P lt ; 0.05 ) ; the simvastatin Minnesota quality score , plasma IL - 1 , NT - proBNP , the APN water average than in the placebo group ( P lt ; 0.05 ) ; simvastatin group , left ventricular ejection fraction ( LVEF ) , left ventricular end-diastolic diameter ( LVEDD ) were significantly improved compared with the placebo group , a statistically significant ( P lt ; 0.05 ) . Placebo group at 3 months and 12 months of observation time point compared to baseline levels , the left ventricular end-diastolic diameter was no significant change in left ventricular ejection fraction is slightly higher than the baseline level , but not statistically significant . Simvastatin IL - 1 , NT - proBNP the APN level compared to their baseline level was significantly lower , the three indicators of the placebo group also must reduce simvastatin reduced levels superior to placebo ( P lt ; 0.05 ). Conclusion : Chronic non-ischemic heart failure patients in the standard treatment on the basis of the anti-heart failure , plus simvastatin 10 mg / day orally its LVEF values ??improve , improve their quality of life ; simvastatin to improve the chronic non - ischemic congestive heart failure may be achieved by the anti-inflammatory effects ; APN and NT-proBNP levels similar trends , with the correlation ; APN may be used for evaluation of chronic non-ischemic heart failure prognosis .
|